Non-culprit coronary artery percutaneous coronary intervention during acute ST-segment elevation myocardial infarction: insights from the APEX-AMI trial.

AIMS To examine the incidence of and propensity for non-culprit interventions performed at the time of the primary percutaneous coronary intervention (PCI) and its association with 90-day outcomes. METHODS AND RESULTS We examined the incidence, propensity for, and associated 90-day outcomes following non-culprit interventions performed at the time of primary PCI among ST-elevation myocardial infarction patients with multi-vessel coronary artery disease (MVD). Of the 5373 patients who underwent primary PCI in the APEX-AMI trial, 2201 had MVD. Of those, 217 (9.9%) underwent non-infarct-related arteries (IRA) PCI, whereas 1984 (90.1%) underwent PCI of the IRA alone. Ninety-day death and death/CHF/shock were higher in the non-IRA group compared with the IRA-only PCI group (12.5 vs. 5.6%, P (log-rank) < 0.001 and 17.4 vs. 12.0%, P (log-rank) = 0.020, respectively). After adjusting for patient and procedural characteristics as well as propensity for performing non-IRA PCI, this procedure remained independently associated with an increased hazard of 90-day mortality [adjusted hazard ratio 2.44, 95% CI (1.55-3.83), P < 0.001]. CONCLUSION Non-culprit coronary interventions were performed at the time of primary PCI in 10% of MVD patients and were significantly associated with increased mortality. Our data support current guideline recommendations discouraging the performance of such procedures in stable primary PCI patients. Prospective randomized study of this issue may be warranted.

[1]  R. Califf,et al.  Scientific evidence underlying the ACC/AHA clinical practice guidelines. , 2009, JAMA.

[2]  Frans Van de Werf,et al.  MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION IN PATIENTS PRESENTING WITH PERSISTENT ST-SEGMENT ELEVATION (ENDING) , 2009 .

[3]  P. Armstrong,et al.  ST-Segment Recovery and Outcome After Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction: Insights From the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Trial , 2008, Circulation.

[4]  Y. Hasin,et al.  Culprit only versus complete coronary revascularization during primary PCI. , 2008, International journal of cardiology.

[5]  Feng Xu,et al.  Multivessel Percutaneous Coronary Intervention in Chinese Patients with Acute Myocardial Infarction and Simple Nonculprit Arteries , 2007, The American journal of the medical sciences.

[6]  Ajai Kumar Jain,et al.  PexeLizumab for Acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: A randomized controlled trial , 2007 .

[7]  G. Richardt,et al.  Multi-vessel stenting during primary percutaneous coronary intervention for acute myocardial infarction , 2007, Clinical Research in Cardiology.

[8]  H. Krumholz,et al.  Trends in Acute Myocardial Infarction in 4 Us States Clinical Characteristics, Quality of Care, and Outcomes , 2022 .

[9]  D. Dudek,et al.  The function of the left ventricle after complete multivessel one-stage percutaneous coronary intervention in patients with acute myocardial infarction. , 2004, The Journal of invasive cardiology.

[10]  C. W. Barth,et al.  Multivessel percutaneous coronary intervention in patients with multivessel disease and acute myocardial infarction. , 2004, American heart journal.

[11]  G. Lamas,et al.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.

[12]  M. Bonardi,et al.  Single vs multivessel treatment during primary angioplasty: results of the multicentre randomised HEpacoat™ for cuLPrit or multivessel stenting for Acute Myocardial Infarction (HELP AMI) Study , 2004, International journal of cardiovascular interventions.

[13]  C. Grines,et al.  Initial experience with multivessel percutaneous coronary intervention during mechanical reperfusion for acute myocardial infarction. , 2001, The American journal of cardiology.

[14]  R. D'Agostino Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. , 2005, Statistics in medicine.

[15]  Javier Botas,et al.  Resultados de la angioplastia primaria en pacientes con enfermedad multivaso , 1998 .

[16]  J. López-Sendón,et al.  [Results of primary angioplasty in patients with multivessel disease]. , 1998, Revista espanola de cardiologia.

[17]  S. Smith,et al.  Outcome of urgent percutaneous transluminal coronary angioplasty in acute myocardial infarction: comparison of single-vessel versus multivessel coronary artery disease. , 1992, American heart journal.

[18]  K. Lee,et al.  Multivessel coronary artery disease: a key predictor of short-term prognosis after reperfusion therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. , 1991, American heart journal.

[19]  B. Rutherford,et al.  Results of primary angioplasty for acute myocardial infarction in patients with multivessel coronary artery disease. , 1990, Journal of the American College of Cardiology.

[20]  Dwight E. Peake,et al.  Thrombolysis in myocardial infarction (TIMI) trial: Phase I. A comparison between intravenous tissue plasminogen activator and intravenous streptokinase , 1988 .

[21]  R Roberts,et al.  Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. , 1987, Circulation.

[22]  Harold T. Dodge,et al.  Thrombolysis inMyocardial Infarction (TIMI) Trial, Phase I:acomparison between intravenous tissue plasminogen activator andintravenous streptokinase* , 1987 .